Algernon Pharmaceuticals (TSE:AGN) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Algernon Pharmaceuticals is set to advance its groundbreaking intravenous DMT stroke research program after successfully divesting its Ifenprodil program to Seyltx. The DMT program, led by Algernon’s subsidiary AGN Neuro, is entering a Phase 2a trial to explore the potential of DMT in promoting neuroplasticity and aiding recovery in ischemic stroke patients without inducing a psychedelic experience. This follows promising results from an earlier Phase 1 trial.
For further insights into TSE:AGN stock, check out TipRanks’ Stock Analysis page.
